Skip to main content
. 2023 May 26;16(6):791. doi: 10.3390/ph16060791

Figure 19.

Figure 19

The relative propensity to induce prostanoid-associated periorbitopathy (PAP) symptoms or other ocular and adjacent tissue cosmetic alterations by four different FP-receptor agonists and an EP2-receptor agonist, OMDI, following topical ocular treatment in ocular hypertensive or glaucoma patients is displayed. The overall severity of the changes induced is shown on a relative scale or graded format ranging from Grade 0 to Grade 3.